Drug Trial Radar · NCT06722235
A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
171
Planned (sponsor's estimate)
Start
Feb 27, 2025
Primary completion
Mar 16, 2028
Study completion Mar 16, 2028
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagitamab, when given just under the skin (subcutaneously \[SC\]), is effective in keeping the platelet count of adults with ITP stable when compared to a placebo. A placebo looks like medicine but doesn't have any active ingredients in it. The participants will be treated with mezagitamab for up to 6 months. During the study, participants will visit their study clinic several times. Participants who complete the TAK-079-3002 study or do not have any response to study treatment by week 16 (according to study criteria) will be given the opportunity to participate in a continuation study to receive open label mezagitamab (if they are eligible and the site is able to open the continuation study).
Conditions
- Immune Thrombocytopenic Purpura (ITP)
Interventions
MezagitamabDrug
Mezagitamab injection administered SC.
PlaceboDrug
Mezagitamab-matching placebo injection administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Durable Platelet ResponseTime frame: Up to Week 24
Locations
124 sites in 18 countries. Site status is shown where the registry gives one.
Genesis Cancer and Blood Institute - SCRI
Hot Springs, Arkansas · Recruiting
USC Norris Comprehensive Cancer Center - Keck Medicine of USC
Los Angeles, California · Recruiting
University of California San Diego Center for Bleeding and Clotting Disorders
San Diego, California · Not yet recruiting
Rocky Mountain Cancer Center
Denver, Colorado · Withdrawn
Georgetown University Medical Center - Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Emory University
Atlanta, Georgia · Recruiting
Innovative Hematology, Inc.
Indianapolis, Indiana · Recruiting
The University of Iowa
Iowa City, Iowa · Recruiting
University Of Louisville Brown Cancer Center
Louisville, Kentucky · Recruiting
American Oncology Partners of Maryland, PA
Bethesda, Maryland · Recruiting
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
University of Massachusetts Chan Medical School
Worcester, Massachusetts · Completed
MidAmerica Cancer Center
Kansas City, Missouri · Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
Montefiore Medical Center
The Bronx, New York · Recruiting
Duke University Hospital
Durham, North Carolina · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Cleveland Clinic
Cleveland, Ohio · Not yet recruiting
Oregon Health & Science University
Portland, Oregon · Recruiting
Perelman Center for Advanced Medicine (PCAM) Hospital of The University of Pennsylvania Penn Blood Disorders Program
Philadelphia, Pennsylvania · Recruiting
Lewis Katz School of Medicine at Temple University
Philadelphia, Pennsylvania · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
University of Washingto
Seattle, Washington · Not yet recruiting
Versiti Wisconsin, Inc
Milwaukee, Wisconsin · Recruiting
Canberra Hospital
Garran, Australian Capital Territory, Australia · Recruiting
Concord Repatriation General Hospital
Concord, New South Wales, Australia · Recruiting
St George Hospital
Kogarah, New South Wales, Australia · Recruiting
University of New South Wales (UNSW) - Liverpool Hospital - Liverpool Cancer Therapy Centre
Liverpool, New South Wales, Australia · Recruiting
Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Peter MacCallum Cancer Centre
Melbourne, Victoria, Australia · Recruiting
Monash University - Australian Centre for Blood Diseases (ACBD)
Melbourne, Victoria, Australia · Recruiting
The Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Fiona Stanley Hospital
Murdoch, Western Australia, Australia · Recruiting
Perth Blood Institute
West Perth, Western Australia, Australia · Recruiting
Medical Center "Fama Medical"
Plovdiv, Bulgaria · Active not recruiting
UMHAT Sv. Ivan Rilski
Sofia, Bulgaria · Active not recruiting
UMHAT SofiaMed, OOD
Sofia, Bulgaria · Active not recruiting
University Multiprofile Hospital for Active Treatment - Prof. Dr. Stoyan Kirkovich AD
Stara Zagora, Bulgaria · Active not recruiting
Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
Sofia, Sofia-Grad, Bulgaria · Active not recruiting
Showing 40 of 124 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.